Gary Kobinger | |
|---|---|
| Born | Gary P. Kobinger Quebec City, Quebec, Canada |
| Alma mater | Université Laval University of Montreal University of Pennsylvania |
| Known for | Development of Ebola vaccine and treatment |
| Scientific career | |
| Fields | |
| Institutions | Galveston National Laboratory |
| Doctoral advisor | Éric A. Cohen |
| Other academic advisors | James Wilson |
Gary P. Kobinger OM MSC is a Canadian immunologist and virologist who is currently the director at the Galveston National Laboratory at the University of Texas.[1] He has held previous professorships at Université Laval, the University of Manitoba, and the University of Pennsylvania.[1] Additionally, he was the chief of the Special Pathogens Unit at the National Microbiology Laboratory (NML) of the Public Health Agency of Canada (PHAC) in Winnipeg, Manitoba, for eight years.[1] Kobinger is known for his critical role in the development of both an effective Ebola vaccine and treatment. His work focuses on the development and evaluation of new vaccine platforms and immunological treatments against emerging and re-emerging viruses that are dangerous to human health.[2]
- ^ a b c "Dr. Gary Kobinger to join GNL as new Director". Galveston National Laboratory. Retrieved 8 March 2022.
- ^ "Gary Kobinger". Universities Canada. Retrieved 8 March 2022.